Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats

J. Klimas, M. Olvedy, K. Ochodnicka-Mackovicova, P. Kruzliak, S. Cacanyiova, F. Kristek, P. Krenek, P. Ochodnicky,

. 2015 ; 19 (8) : 1965-74. [pub] 20150312

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010463

Since the identification of the alternative angiotensin converting enzyme (ACE)2/Ang-(1-7)/Mas receptor axis, renin-angiotensin system (RAS) is a new complex target for a pharmacological intervention. We investigated the expression of RAS components in the heart and kidney during the development of hypertension and its perinatal treatment with losartan in young spontaneously hypertensive rats (SHR). Expressions of RAS genes were studied by the RT-PCR in the left ventricle and kidney of rats: normotensive Wistar, untreated SHR, SHR treated with losartan since perinatal period until week 9 of age (20 mg/kg/day) and SHR treated with losartan only until week 4 of age and discontinued until week 9. In the hypertrophied left ventricle of SHR, cardiac expressions of Ace and Mas were decreased while those of AT1 receptor (Agtr1a) and Ace2 were unchanged. Continuous losartan administration reduced LV weight (0.43 ± 0.02; P < 0.05 versus SHR) but did not influence altered cardiac RAS expression. Increased blood pressure in SHR (149 ± 2 in SHR versus 109 ± 2 mmHg in Wistar; P < 0.05) was associated with a lower renal expressions of renin, Agtr1a and Mas and with an increase in ACE2. Continuous losartan administration lowered blood pressure to control levels (105 ± 3 mmHg; P < 0.05 versus SHR), however, only renal renin and ACE2 were significantly up-regulated (for both P < 0.05 versus SHR). Conclusively, prevention of hypertension and LV hypertrophy development by losartan was unrelated to cardiac or renal expression of Mas. Increased renal Ace2, and its further increase by losartan suggests the influence of locally generated Ang-(1-7) in organ response to the developing hypertension in SHRs.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010463
003      
CZ-PrNML
005      
20160414121428.0
007      
ta
008      
160408s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jcmm.12573 $2 doi
024    7_
$a 10.1111/jcmm.12573 $2 doi
035    __
$a (PubMed)25766467
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Klimas, Jan $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia.
245    10
$a Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats / $c J. Klimas, M. Olvedy, K. Ochodnicka-Mackovicova, P. Kruzliak, S. Cacanyiova, F. Kristek, P. Krenek, P. Ochodnicky,
520    9_
$a Since the identification of the alternative angiotensin converting enzyme (ACE)2/Ang-(1-7)/Mas receptor axis, renin-angiotensin system (RAS) is a new complex target for a pharmacological intervention. We investigated the expression of RAS components in the heart and kidney during the development of hypertension and its perinatal treatment with losartan in young spontaneously hypertensive rats (SHR). Expressions of RAS genes were studied by the RT-PCR in the left ventricle and kidney of rats: normotensive Wistar, untreated SHR, SHR treated with losartan since perinatal period until week 9 of age (20 mg/kg/day) and SHR treated with losartan only until week 4 of age and discontinued until week 9. In the hypertrophied left ventricle of SHR, cardiac expressions of Ace and Mas were decreased while those of AT1 receptor (Agtr1a) and Ace2 were unchanged. Continuous losartan administration reduced LV weight (0.43 ± 0.02; P < 0.05 versus SHR) but did not influence altered cardiac RAS expression. Increased blood pressure in SHR (149 ± 2 in SHR versus 109 ± 2 mmHg in Wistar; P < 0.05) was associated with a lower renal expressions of renin, Agtr1a and Mas and with an increase in ACE2. Continuous losartan administration lowered blood pressure to control levels (105 ± 3 mmHg; P < 0.05 versus SHR), however, only renal renin and ACE2 were significantly up-regulated (for both P < 0.05 versus SHR). Conclusively, prevention of hypertension and LV hypertrophy development by losartan was unrelated to cardiac or renal expression of Mas. Increased renal Ace2, and its further increase by losartan suggests the influence of locally generated Ang-(1-7) in organ response to the developing hypertension in SHRs.
650    _2
$a zvířata $7 D000818
650    _2
$a novorozená zvířata $7 D000831
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese $x účinky léků $7 D005786
650    _2
$a srdeční komory $x účinky léků $x metabolismus $x patologie $7 D006352
650    _2
$a hypertenze $x komplikace $x farmakoterapie $x genetika $x prevence a kontrola $7 D006973
650    _2
$a hypertrofie levé komory srdeční $x komplikace $x farmakoterapie $x genetika $x prevence a kontrola $7 D017379
650    _2
$a ledviny $x účinky léků $x enzymologie $7 D007668
650    _2
$a losartan $x aplikace a dávkování $x farmakologie $x terapeutické užití $7 D019808
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myokard $x enzymologie $7 D009206
650    _2
$a oxid dusnatý $x metabolismus $7 D009569
650    _2
$a angiotensin konvertující enzym $x metabolismus $7 D007703
650    _2
$a protoonkogenní proteiny $x metabolismus $7 D011518
650    _2
$a messenger RNA $x genetika $x metabolismus $7 D012333
650    _2
$a potkani inbrední SHR $7 D011918
650    _2
$a receptory spřažené s G-proteiny $x metabolismus $7 D043562
650    _2
$a renin-angiotensin systém $x účinky léků $x genetika $7 D012084
650    _2
$a signální transdukce $x účinky léků $7 D015398
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Olvedy, Michael $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia.
700    1_
$a Ochodnicka-Mackovicova, Katarina $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia.
700    1_
$a Kruzliak, Peter $u Department of Cardiovascular Diseases, International Clinical Research Centre, St. Anne's University Hospital and Masaryk University, Brno, Czech Republic.
700    1_
$a Cacanyiova, Sona $u Institute of Normal and Pathological Physiology, Centre of Excellence for Cardiovascular Research, Slovak Academy of Sciences, Bratislava, Slovakia.
700    1_
$a Kristek, Frantisek $u Institute of Normal and Pathological Physiology, Centre of Excellence for Cardiovascular Research, Slovak Academy of Sciences, Bratislava, Slovakia.
700    1_
$a Krenek, Peter $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia.
700    1_
$a Ochodnicky, Peter $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia.
773    0_
$w MED00006785 $t Journal of cellular and molecular medicine $x 1582-4934 $g Roč. 19, č. 8 (2015), s. 1965-74
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25766467 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20160414121513 $b ABA008
999    __
$a ok $b bmc $g 1113892 $s 934831
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 19 $c 8 $d 1965-74 $e 20150312 $i 1582-4934 $m Journal of cellular and molecular medicine $n J Cell Mol Med $x MED00006785
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...